Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
FTSE 250 movers: Spire, Tate & Lyle surge on bid hopes
(Sharecast News) - FTSE 250 (MCX) 22,757.00 1.01%] UK private hospital group Spire Healthcare on Thursday said it had received a £1bn buyout bid from Toscafund Asset Management, sending its shares surging by 46%.
The 250p-a-share proposal represents a premium of about 66% to Spire's last closing price, Spire said, adding that it would recommend it to shareholders if a formal offer was tabled.
Toscafund, which has an 18% stake in the company, has until June 11 to make a firm bid or walk away under UK takeover rules.
In a separate statement, Spire said it trading in the first four months of the year to April 2026 had been in line with our expectations as private patient revenue continued to grow strongly, particularly self-pay; with NHS revenue also as expected.
The company said it expected full-year earnings to be "broadly" in line with expectations.
Spire in January said it was in preliminary talks with investment firms Bridgepoint and Triton regarding a potential takeover, however Triton withdrew in March.
Tate & Lyle surged on Thursday as it confirmed it is in talks with US rival Ingredion about a possible takeover at 615p per share.
Responding to press speculation, Tate said that under the proposal - which followed a number of earlier approaches from Ingredion - its shareholders would get 595p per share in cash and the right to receive a final dividend of up to 13p per share and an interim dividend of up to 7p.
"The board and Ingredion are in discussions regarding the proposal," it said, adding that there can be no certainty that any offer will be made, nor as to the final terms on which any offer might be made.
A further announcement will be made when appropriate, the company said.
Under UK takeover rules, Ingredion has until 1700 BST on 11 June to make a firm offer or walk away.
Luxury watch retailer Watches of Switzerland said on Thursday that full-year adjusted underlying earnings were now expected to come in ahead of previous guidance after group revenue and sales grew.
Watches of Switzerland said revenues grew 13% at constant currency to £1.83bn, or 11% excluding its 53rd week, with demand for key luxury brands remaining robust across the UK and US. Luxury watch sales also grew 13% at constant currency, while luxury jewellery outperformed with an 18% uplift.
The FTSE 250-listed firm highlighted that the US had again led the charge, with revenues up 24% at constant currency and now accounting for more than half of group sales and profit. Retail revenue in the region climbed 25%, supported by broad‑based growth across brands, categories and regions. UK revenues increased 5% year‑on‑year, with momentum improving through the second half, particularly in luxury jewellery and pre‑owned.
Pre‑owned sales rose 22%, with further rollout of Rolex Certified Pre‑Owned in the UK, while e-commerce revenue grew 21% at constant currency.
As a result, adjusted underlying earnings were now expected to land between £152m and £155m, ahead of prior guidance, reflecting the stronger top‑line performance. Net debt closed the year at £57m following its acquisition of Deutsch & Deutsch.
Looking ahead, Watches of Switzerland said its FY27 guidance of 5% to 10% constant currency revenue growth and a 40 to 80 basis point expansion to its adjusted EBIT margin reflected confirmed supply, pricing and showroom plans, while noting limited direct exposure to geopolitical hotspots and tourist‑driven demand.
FTSE 250 - Risers
Spire Healthcare Group (SPI) 220.50p 46.61% Tate & Lyle (TATE) 546.00p 45.41% Watches of Switzerland Group (WOSG) 618.00p 16.38% Aston Martin Lagonda Global Holdings (AML) 49.54p 6.31% Premier Foods (PFD) 205.80p 4.41% ITV (ITV) 80.95p 4.31% Dr. Martens (DOCS) 63.30p 4.28% RTW Biotech Opportunities Ltd (RTW) 2.19p 3.79% IntegraFin Holding (IHP) 334.00p 3.57% CVS Group (CVSG) 1,188.00p 3.31%
FTSE 250 - Fallers
Pagegroup (PAGE) 118.20p -5.21% Ceres Power Holdings (CWR) 725.50p -2.42% Partners Group Private Equity Limited. (EUR) (PEY) 8.16p -2.39% Oxford Biomedica (OXB) 614.00p -2.38% Safestore Holdings (SAFE) 649.50p -1.89% HGCapital Trust (HGT) 345.00p -1.85% Greencoat UK Wind (UKW) 99.75p -1.82% Hays (HAS) 30.34p -1.81% Raspberry PI Holdings (RPI) 697.00p -1.73% Drax Group (DRX) 855.00p -1.72%
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.